In this survey of RTKs as regulatory controls of NAFLD, we arrive at a picture where activation of some RTKs (HGF, FGFR1) and inhibition of others (EGFR, AXL, FGFR4 and VEGFR) have found to be useful in tackling NAFLD. This evidence concerns the gene FGFR4 and metabolic dysfunction-associated steatotic liver disease.